Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Drops By 10.0%

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 349,900 shares, a drop of 10.0% from the March 31st total of 388,800 shares. Based on an average trading volume of 278,000 shares, the days-to-cover ratio is currently 1.3 days. Currently, 2.5% of the company's shares are sold short.

Hedge Funds Weigh In On Immix Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC boosted its stake in shares of Immix Biopharma by 26.4% in the 3rd quarter. Commonwealth Equity Services LLC now owns 28,855 shares of the company's stock valued at $99,000 after buying an additional 6,030 shares during the period. OLD National Bancorp IN acquired a new stake in shares of Immix Biopharma during the 4th quarter worth about $69,000. Imprint Wealth LLC lifted its stake in Immix Biopharma by 49.4% during the fourth quarter. Imprint Wealth LLC now owns 34,483 shares of the company's stock worth $239,000 after purchasing an additional 11,400 shares during the last quarter. Tocqueville Asset Management L.P. purchased a new stake in Immix Biopharma during the third quarter worth approximately $41,000. Finally, Jump Financial LLC purchased a new stake in Immix Biopharma during the fourth quarter worth approximately $128,000. Hedge funds and other institutional investors own 11.26% of the company's stock.

Immix Biopharma Trading Down 0.5 %

Immix Biopharma stock traded down $0.01 during midday trading on Monday, reaching $2.12. 227,308 shares of the stock traded hands, compared to its average volume of 253,426. The company has a 50-day simple moving average of $2.89 and a two-hundred day simple moving average of $4.02. The firm has a market cap of $55.97 million, a PE ratio of -2.38 and a beta of 0.06. Immix Biopharma has a 12-month low of $1.40 and a 12-month high of $7.75.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its quarterly earnings data on Friday, March 29th. The company reported ($0.24) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Immix Biopharma will post -0.91 earnings per share for the current year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.